Hi NZT,
Fiona Wood shared the following comments about the trial with Pharmaxis:“This exploratory clinical study has significantly enhanced our understanding of the role of LOX enzymes in scarring and the scar process itself. PXS-6302 safely inhibits these key enzymes to a significant degree and leads directly to an unprecedented change to the scar composition that we have not seen with any other form of treatment. We estimate that up to 50% of the excess collagen in these patients’ scars has been removed and while the length of this Phase 1c safety study was not sufficient to change the appearance of an established scar the remodelling process will be ongoing and I’m confident we would see an improvement in scar appearance and physical characteristics if we observed them for longer.
https://www.fionawoodfoundation.org.au/news-and-events/solaria-scar-cream-trial
Kpax
Add to My Watchlist
What is My Watchlist?
